With a higher affinity for the ligands CD80 and CD86 on antigen-presenting cells (APCs) than the co-stimulation receptor CD28 on T cells, the interaction between CTLA4 and its ligands suppresses T-cell activity, thereby promoting tumor growth. This evidence concerns the gene CD86 and neoplasm.